Tashatuvango / shutterstock.com

18 April 2017Americas

UC, Berkeley appeals to Federal Circuit in CRISPR patent clash

The University of California (UC), Berkeley and the University of Vienna have appealed against the Patent Trial and Appeal Board's (PTAB) decision in the dispute over CRISPR technology.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

PTAB says Broad's CRISPR patents do not interfere with UC Berkeley's

16 February 2017 The Broad Institute of Harvard and MIT’s patents concerning CRISPR technology do not interfere with patent claims filed by the University of California, Berkeley and the University of Vienna.

Broad Institute takes three lines of attack in CRISPR appeal filing

26 October 2017 The Broad Institute of Harvard and MIT has adopted three major arguments in its response to the University of California, Berkeley’s appeal against a patent finding on the CRISPR technology.

More on this story

PTAB says Broad's CRISPR patents do not interfere with UC Berkeley's

16 February 2017 The Broad Institute of Harvard and MIT’s patents concerning CRISPR technology do not interfere with patent claims filed by the University of California, Berkeley and the University of Vienna.

Broad Institute takes three lines of attack in CRISPR appeal filing

26 October 2017 The Broad Institute of Harvard and MIT has adopted three major arguments in its response to the University of California, Berkeley’s appeal against a patent finding on the CRISPR technology.

More on this story

PTAB says Broad's CRISPR patents do not interfere with UC Berkeley's

16 February 2017 The Broad Institute of Harvard and MIT’s patents concerning CRISPR technology do not interfere with patent claims filed by the University of California, Berkeley and the University of Vienna.

Broad Institute takes three lines of attack in CRISPR appeal filing

26 October 2017 The Broad Institute of Harvard and MIT has adopted three major arguments in its response to the University of California, Berkeley’s appeal against a patent finding on the CRISPR technology.

More features

Sandoz lands reduced antitrust award of $70m

New president’s to-do list: Patent bills, non-competes, USPTO director?

Sanofi subsidiary fends off $450m trade secrets case

Regulatory expert joins White & Case

Teva faces $500m fine for antitrust breaches over MS drug

UK Budget: A missed opportunity?

Pfizer infringed haemophilia therapy patent, says court

Cooley adds ex-Gowling partner